News

According to preliminary findings from the phase Ib KEYNOTE-173 trial, combining the PD-1 inhibitor pembrolizumab with platinum/taxane chemotherapy led to high rates of pathologic complete response in patients with locally advanced triple-negative breast cancer.

The indication for aprepitant injectable emulsion has been expanded by the FDA to include a 2-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

Lori J. Wirth, MD, discusses the current treatment options for patients with advanced thyroid cancers, in addition to some of the trials that are currently enrolling at her center. She also highlights early data that have been presented for targeted therapies in advanced thyroid cancer.

Subcutaneous use of trastuzumab and hyaluronidase-oysk injection has been approved by the FDA in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen.

Adjuvant external beam radiation therapy was associated with worse overall survival and disease-specific survival in patients with locally invasive papillary thyroid carcinoma, a new retrospective cohort study has found.

Guardant360—a 73-gene next-generation sequencing panel—detected all of the guideline-recommended biomarkers in patients newly diagnosed with metastatic non–small cell lung cancer at a similar rate, but in a faster turnaround time than tissue genotyping, according to data from the NILE study.

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.

In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.

Based on findings from the phase III ARAMIS trial, a new drug application for darolutamide has been submitted to the FDA seeking the&nbsp;investigational agent&#39;s approval as a treatment for&nbsp;patients with nonmetastatic castration-resistant prostate cancer, according to&nbsp;the codevelopers of the investigational agent, Bayer and Orion Corporation.<br /> &nbsp;

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.

According to Huma Q. Rana, MD, genetic testing provides valuable benefit in the treatment landscape of gynecologic cancers. It can inform physicians of the individual and&nbsp;familial risk for developing a malignancy, alert patients of potential screening and preventative measures, and guide selection of potential targeted therapies.

In an 8 to 5 vote, the FDA&#39;s&nbsp;Oncologic Drugs Advisory Committee decided against the&nbsp;accelerated approval of a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma. Instead, the committee recommended delaying a decision on the NDA until&nbsp;results are available from the pivotal phase III BOSTON trial.

Based on data from the phase III AUGMENT trial, a supplemental new drug application for the&nbsp;R²&nbsp;regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA&nbsp;as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.

AstraZeneca and Merck, the codevelopers of olaparib, have announced that findings from the phase III POLO trial showed use of the PARP inhibitor as a frontline maintenance for patients with germline <em>BRCA</em>-mutated metastatic adenocarcinoma of the pancreas&nbsp;significantly reduced the risk of disease progression or death versus placebo.

In an interview with <em>Targeted Oncology&nbsp;</em>during the 2019 TCT meeting, Frederick L. Locke, MD, discusses the optimal management of CAR T-cell therapy-related adverse events.

Based on data from an ongoing preliminary trial, CD30-targeting chimeric antigen receptor T cells are safe and active in the treatment of patients with relapsed/refractory Hodgkin lymphoma.

According to findings from the phase III COLUMBA trial in patients with relapsed/refractory multiple myeloma, a&nbsp;subcutaneous formulation of daratumumab &nbsp;is noninferior in terms of inefficacy and pharmacokinetics to the standard&nbsp;intravenous daratumumab.

All but 1 of the first 19 patients with relapsed/refractory AML randomized to receive iodine-131 apamistamab had a complete response and went on to have successful engraftment of allogeneic hematopoietic stem cell transplant,&nbsp;according to preliminary results from the ongoing, randomized, phase III SIERRA trial that were presented at the 2019 Transplantation and Cellular Therapy Meetings.&nbsp;

Masatoshi Kudo, MD, PhD,&nbsp;discusses the results from the REFLECT trial and an analysis presented at the 2019 Gastrointestinal Cancers Symposium, as well as other research currently ongoing for this patient population.

Based on data from the phase III TAGS trial, TAS-102 has been approved by the FDA as a treatment for&nbsp;adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

The FDA has granted an orphan drug designation to the investigational agent etoposide toniribate for the treatment of patients with relapsed/refractory biliary tract cancer, according to Imbrium Therapeutics, the company developing the topoisomerase II inhibitor.

Daneng Li, MD,&nbsp;sheds light on some of the currently available regimens and ongoing research efforts being conducted in HCC and NETs.

Adding ibrutinib to&nbsp;CAR T-cell therapy led to improved responses in patients with relapsed/refractory chronic lymphocytic leukemia, according to preliminary findings presented at&nbsp;the 2019 Transplantation and Cellular Therapy Meetings.

Ruben A. Mesa, MD,&nbsp;discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.

Reduced-dose rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone had a similar complete response rate, progression-free survival, and overall survival compared with standard-dose R-CHOP or previous dose-adjusted R-CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma.

Neelima Denduluri, MD, discusses each CDK4/6 inhibitor as potential first-line and second-line therapies based on the data from the PALOMA-2, MONALEESA-2 and -7, and MONARCH 3 trials, which led to their approvals.

In findings from a final PFS analysis of the phase III TOURMALINE-MM3 trial presented during the&nbsp;2019 Transplantation and Cellular Therapy Meetings, 2-year&nbsp;maintenance therapy with the oral proteasome inhibitor ixazomib following autologous stem cell transplantation improved progression-free survival in patients with multiple myeloma.

A supplemental new drug application for ivosidenib has been granted a priority review designation by the FDA&nbsp;for the frontline treatment of patients <em>IDH1</em>-mutant acute myeloid leukemia who are ineligible for standard chemotherapy, according to&nbsp;Agios, the manufacturer of ivosidenib.

Merck,&nbsp;the developer of pembrolizumab, has announced that the coprimary endpoints of the&nbsp;KEYNOTE-240 trial were not met, as adding the agent&nbsp;to best supportive care failed&nbsp;to improve&nbsp;progression-free or overall survival in patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy.

Pembrolizumab has been granted a priority review designation by the FDA for the treatment of patients with advanced small cell lung cancer whose disease has progressed following &ge;2 prior lines of therapy.